Stryker Debt to Equity Ratio 2010-2025 | SYK
Current and historical debt to equity ratio values for Stryker (SYK) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Stryker debt/equity for the three months ending March 31, 2025 was 0.69.
| Stryker Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $25.08B | $20.93B | 1.20 |
| 2024-12-31 | $22.34B | $20.63B | 1.08 |
| 2024-09-30 | $23.68B | $20.15B | 1.18 |
| 2024-06-30 | $19.37B | $19.76B | 0.98 |
| 2024-03-31 | $20.23B | $19.17B | 1.06 |
| 2023-12-31 | $21.32B | $18.59B | 1.15 |
| 2023-09-30 | $20.14B | $17.91B | 1.13 |
| 2023-06-30 | $20.05B | $17.36B | 1.16 |
| 2023-03-31 | $19.94B | $16.90B | 1.18 |
| 2022-12-31 | $20.27B | $16.62B | 1.22 |
| 2022-09-30 | $19.52B | $16.46B | 1.19 |
| 2022-06-30 | $20.36B | $15.67B | 1.30 |
| 2022-03-31 | $21.09B | $15.05B | 1.40 |
| 2021-12-31 | $19.75B | $14.88B | 1.33 |
| 2021-09-30 | $19.97B | $14.18B | 1.41 |
| 2021-06-30 | $19.88B | $13.82B | 1.44 |
| 2021-03-31 | $19.95B | $13.50B | 1.48 |
| 2020-12-31 | $21.25B | $13.08B | 1.62 |
| 2020-09-30 | $19.30B | $12.99B | 1.49 |
| 2020-06-30 | $18.73B | $12.75B | 1.47 |
| 2020-03-31 | $16.33B | $13.12B | 1.25 |
| 2019-12-31 | $17.36B | $12.81B | 1.36 |
| 2019-09-30 | $14.34B | $12.32B | 1.17 |
| 2019-06-30 | $14.41B | $11.94B | 1.21 |
| 2019-03-31 | $14.24B | $11.69B | 1.22 |
| 2018-12-31 | $15.50B | $11.73B | 1.32 |
| 2018-09-30 | $12.22B | $9.86B | 1.24 |
| 2018-06-30 | $12.11B | $9.46B | 1.28 |
| 2018-03-31 | $12.91B | $9.22B | 1.40 |
| 2017-12-31 | $12.22B | $9.98B | 1.22 |
| 2017-09-30 | $11.06B | $10.43B | 1.06 |
| 2017-06-30 | $11.26B | $10.04B | 1.12 |
| 2017-03-31 | $10.81B | $9.70B | 1.11 |
| 2016-12-31 | $10.89B | $9.55B | 1.14 |
| 2016-09-30 | $10.86B | $9.33B | 1.16 |
| 2016-06-30 | $11.42B | $9.10B | 1.26 |
| 2016-03-31 | $10.86B | $8.81B | 1.23 |
| 2015-12-31 | $7.71B | $8.51B | 0.91 |
| 2015-09-30 | $7.43B | $8.48B | 0.88 |
| 2015-06-30 | $8.31B | $8.51B | 0.98 |
| 2015-03-31 | $8.26B | $8.32B | 0.99 |
| 2014-12-31 | $8.68B | $8.60B | 1.01 |
| 2014-09-30 | $8.89B | $8.62B | 1.03 |
| 2014-06-30 | $8.23B | $9.00B | 0.91 |
| 2014-03-31 | $7.10B | $9.06B | 0.78 |
| 2013-12-31 | $6.70B | $9.05B | 0.74 |
| 2013-09-30 | $6.15B | $8.74B | 0.70 |
| 2013-06-30 | $5.78B | $8.60B | 0.67 |
| 2013-03-31 | $5.63B | $8.46B | 0.67 |
| 2012-12-31 | $4.61B | $8.60B | 0.54 |
| 2012-09-30 | $4.42B | $8.36B | 0.53 |
| 2012-06-30 | $4.31B | $7.95B | 0.54 |
| 2012-03-31 | $4.44B | $8.02B | 0.55 |
| 2011-12-31 | $4.46B | $7.68B | 0.58 |
| 2011-09-30 | $4.53B | $7.56B | 0.60 |
| 2011-06-30 | $3.82B | $7.78B | 0.49 |
| 2011-03-31 | $3.78B | $7.45B | 0.51 |
| 2010-12-31 | $3.72B | $7.17B | 0.52 |
| 2010-09-30 | $3.47B | $7.31B | 0.47 |
| 2010-06-30 | $3.32B | $6.75B | 0.49 |
| 2010-03-31 | $3.43B | $6.67B | 0.51 |
| 2009-12-31 | $2.48B | $6.60B | 0.38 |
| 2009-09-30 | $2.02B | $6.44B | 0.31 |
| 2009-06-30 | $1.87B | $6.06B | 0.31 |
| 2009-03-31 | $1.96B | $5.63B | 0.35 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $148.668B | $22.595B |
| Stryker Corporation is a medical device company operating in the global orthopedic market. The company has three business segments: Orthopaedics, MedSurg and Neurotechnology & Spine. Orthopaedic?products include implants used in hip and knee joint replacements and trauma and extremities surgeries. MedSurg?products consists of surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment and reprocessed and remanufactured medical devices. Neurotechnology & Spine division includes both neurosurgical and neurovascular devices. These includes products used for minimally invasive endovascular techniques; traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. Spinal implant product offering includes cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $232.025B | 27.90 |
| Boston Scientific (BSX) | United States | $151.510B | 37.93 |
| EssilorLuxottica (ESLOY) | France | $135.285B | 0.00 |
| Medtronic (MDT) | Ireland | $113.608B | 16.10 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.270B | 0.00 |
| Haleon (HLN) | United Kingdom | $45.147B | 25.77 |
| ResMed (RMD) | United States | $37.623B | 28.26 |
| GE HealthCare Technologies (GEHC) | United States | $34.433B | 16.35 |
| Agilent Technologies (A) | United States | $34.375B | 22.41 |
| Terumo (TRUMY) | Japan | $24.785B | 32.19 |
| Koninklijke Philips (PHG) | Netherlands | $23.187B | 16.27 |
| Insulet (PODD) | United States | $20.867B | 81.91 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.493B | 11.88 |
| Baxter (BAX) | United States | $15.734B | 11.75 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.038B | 0.00 |
| Demant (WILYY) | Denmark | $8.971B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.823B | 23.74 |
| Lantheus Holdings (LNTH) | United States | $5.702B | 14.38 |
| Prestige Consumer Healthcare (PBH) | United States | $3.885B | 17.35 |
| Perrigo (PRGO) | Ireland | $3.731B | 9.46 |
| Haemonetics (HAE) | United States | $3.650B | 16.62 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.415B | 28.38 |
| ICU Medical (ICUI) | United States | $3.262B | 24.05 |
| QuidelOrtho (QDEL) | United States | $2.084B | 14.34 |
| LeMaitre Vascular (LMAT) | United States | $1.896B | 42.38 |
| AtriCure (ATRC) | United States | $1.566B | 0.00 |
| Acuren (TIC) | United States | $1.379B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.286B | 13.06 |
| Phibro Animal Health (PAHC) | United States | $1.221B | 15.61 |
| Green Thumb Industries (GTBIF) | United States | $1.211B | 27.24 |
| Neogen (NEOG) | United States | $1.137B | 14.56 |
| BioLife Solutions (BLFS) | United States | $1.071B | 0.00 |
| InMode (INMD) | Israel | $0.971B | 9.78 |
| Kestra Medical Technologies (KMTS) | United States | $0.810B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.703B | 0.00 |
| Owens & Minor (OMI) | United States | $0.695B | 5.76 |
| Curaleaf Holdings (CURLF) | Canada | $0.643B | 0.00 |
| CeriBell (CBLL) | United States | $0.619B | 0.00 |
| Evolus (EOLS) | United States | $0.597B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.594B | 0.00 |
| Valneva SE (VALN) | France | $0.497B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.465B | 0.00 |
| Surmodics (SRDX) | United States | $0.429B | 0.00 |
| SNDL (SNDL) | Canada | $0.363B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.347B | 12.77 |
| Quanterix (QTRX) | United States | $0.327B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.322B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.299B | 0.00 |
| Cerus (CERS) | United States | $0.279B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.277B | 23.40 |
| Sanara MedTech (SMTI) | United States | $0.269B | 0.00 |
| ZimVie (ZIMV) | United States | $0.268B | 12.19 |
| Cresco Labs (CRLBF) | United States | $0.265B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.256B | 76.00 |
| Brainsway (BWAY) | Israel | $0.243B | 64.35 |
| OraSure Technologies (OSUR) | United States | $0.227B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.226B | 0.00 |
| Biote (BTMD) | United States | $0.222B | 6.25 |
| TriSalus Life Sciences (TLSI) | United States | $0.196B | 0.00 |
| Organigram Global (OGI) | Canada | $0.192B | 0.00 |
| High Tide (HITI) | Canada | $0.190B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.187B | 15.23 |
| Omeros (OMER) | United States | $0.183B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.181B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.150B | 0.00 |
| Exagen (XGN) | United States | $0.148B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.127B | 15.61 |
| TerrAscend (TSNDF) | Canada | $0.101B | 0.00 |
| Fonar (FONR) | United States | $0.097B | 12.47 |
| MacroGenics (MGNX) | United States | $0.093B | 0.00 |
| Jin Medical (ZJYL) | China | $0.091B | 0.00 |
| Apyx Medical (APYX) | United States | $0.090B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.085B | 0.00 |
| Veru (VERU) | United States | $0.085B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.078B | 0.00 |
| Zynex (ZYXI) | United States | $0.073B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Agape ATP (ATPC) | $0.069B | 0.00 | |
| Jushi Holdings (JUSHF) | United States | $0.067B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.066B | 0.00 |
| ImmuCell (ICCC) | United States | $0.060B | 0.00 |
| Nephros (NEPH) | United States | $0.041B | 55.57 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 12.84 |
| Safety Shot (SHOT) | United States | $0.032B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.032B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |